摘要
目的探讨原发性肝癌与乙型肝炎病毒(HBV)YMDD变异的关系。方法应用实时荧光聚合酶链反应(PCR)技术检测HBV YMDD变异情况,结合血清生化指标丙氨酸氨基转移酶(ALT)及天门冬氨酸氨基转移酶(AST),分析慢性乙型肝炎(CHB)、肝硬化(LC)和肝细胞癌(HCC)各组变异与肝癌有无相关性。结果 HCC组、LC组、CHB组HBV YMDD变异率分别为11.67%(7/60)、31.67%(19/60)、26.67%(16/60)。HCC组、LC组及CHB组中ALT活性分别为56(25～113)、61(23～301)、58(31～267)U/L,而AST活性分别为105(39～137)、64(25～109)和55(33～214)U/L。60例HCC患者中有HBV YMDD突变7例,突变率为11.67%。结论肝癌发生与HBV YMDD变异不存在明显相关性。AST比ALT更能反应HBV引起肝脏损伤的严重程度,而ALT是与HBV YMDD变异有关的较为敏感的肝功能指标,有利于病情监测。
Objective To investigate the correlation of primary hepatic carcinoma and hepatitis B virus （HBV） YMDD variation. Methods By real-time fluorescence polymerase chain reaction （ PCR）, the detection of HBV YMDD variation was performed. Combined with the results of serum biochemical markers, alanine aminotransferase （ALT） and aspartate aminotransferase （AST）, the correlation of primary hepatic carcinoma with chronic hepatitis B （CHB）, liver cirrhosis （LC） and hepatocellular carcinoma （HCC） was analyzed. Results In HCC group, LC group and CHB group, HBV YMDD mutation rates were 11.67% （7/60）, 31.67% （19/60） and 26.67% （16/60）. In HCC group, LC group and CHB group, the activities of ALT were 56 （25-113）, 61 （23-301） and 58 （31-267） U/L, and the activities of AST were 105（39-137）, 64 （25-109） and 55 （33-214） U/L. In 60 cases of HCC, 7 cases showed positive HBV YMDD mutations, and the mutation rate was 11.67%. Conclusions The occurrence of primary hepatic carcinoma and HBV YMDD variation does not exist significant correlation. AST can reflect the severity of liver injury induced by HBV better than ALT. ALT is a sensitive indicator of liver function associated with HBV YMDD variation, and is conducive to disease monitoring.
出处
《检验医学》
CAS
2012年第12期1047-1049,共3页
Laboratory Medicine
关键词
YMDD变异
乙型肝炎病毒
聚合酶链反应
原发性肝癌
YMDD variation
Hepatitis B virus
Polymerase chain reaction
Primary hepatic carcinoma
